Research library

C

grade

Leuprorelin may reduce proliferation and migration of endometrial cancer cells, but its clinical relevance in humans is not established.

Not reported in abstract.

summary

C

grade

Leuprorelin may inhibit endometrial cancer progression by disrupting the ELAVL1/VEGFA axis, but further studies are needed to confirm these findings in humans.

Not reported in abstract.

summary

C

grade

The study suggests that JCPyV-derived virus-like particles could inhibit tumor growth in metastatic CRPC, but no significant survival benefits were observed compared to standard treatments.

No significant differences in survival were observed among the MOCK, ENZ/LEU, and PSAtk-VLP/GCV groups (log-rank test, p = 0.7351).

summary

B

grade

Leuprorelin did not significantly reduce liver volume in women with severe polycystic liver disease and was associated with substantial adverse effects.

Median liver growth rate 4.04 [-4.62 to 6.84] %/year in leuprorelin group vs. 11.0 [0.70-13.2] %/year in standard care group, p=0.15.

summary

B

grade

In patients with uterine leiomyoma and unexplained erythrocytosis, consider myomatous erythrocytosis syndrome and the potential benefits of surgical intervention.

Hemoglobin was 20.1 g/dL at presentation, reduced to 11.4 g/dL at one-month follow-up.

summary

B

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

A

grade

Linzagolix showed comparable efficacy to leuprorelin for heavy menstrual bleeding, with a faster onset of action, but further studies are needed to assess long-term safety.

89.9% of patients in the linzagolix group achieved a total PBAC score <10 from Weeks 6 to 12, 95% CI 83.7, 94.4.

summary

B

grade

Caution is warranted when initiating LHRH agonist therapy in patients with known or suspected meningiomas, as it may be associated with tumor growth.

Not reported in abstract.

summary

B

grade

The AI model shows promise in predicting recurrence scores but should not replace genomic testing as the gold standard.

AUC of 0.898 for identifying recurrence score ≥26.

summary

B

grade

Conventional diagnostic methods may miss metastatic prostate cancer; comprehensive approaches, including advanced imaging, are crucial.

summary

D

grade

Peptide therapeutics show potential in treating solid tumors, with AI enhancing their design and discovery.

summary

C

grade

Leuprorelin-decorated nanoparticles show promise in improving breast cancer treatment efficacy and safety in preclinical models, but human trials are needed to confirm these findings.

Particle size of 154.23 ± 7.51 nm.

summary

A

grade

Leuprolide 22.5 mg showed superior PSA reduction but was associated with more adverse events compared to goserelin 10.8 mg, which had its own risks.

Not reported in abstract.

summary

A

grade

This trial is investigating vaginal radiofrequency as a treatment for dryness in breast cancer patients, but results are not yet available.

Not reported in abstract.

summary

B

grade

This study highlights the substantial clinical overlap among ATP1A3-related disorders, indicating a need for a unified diagnostic framework.

41 patients with ATP1A3 variants included.

summary

B

grade

Leuprorelin treatment for ≥3 years does not show a significant benefit over 2 years in overall disease-free survival for premenopausal breast cancer patients, but may offer advantages for higher-risk individuals.

HR 0.944, 95% CI 0.486-1.8392 for DFS between ≥3 years and 2 years.

summary

B

grade

This case highlights a possible link between Niemann-Pick Disease Type C and central precocious puberty, warranting further investigation.

Height velocity was 0.4 SDS at the first year of follow-up.

summary

B

grade

Half of the drugs granted pediatric testing waivers are used in children, suggesting a need for post-approval studies to ensure safety.

Median summed users was 17 (IQR, 3-102).

summary

A

grade

Low-dose Ganirelix may help reduce LH levels and improve hormonal balance in women with PCOS, but further research is needed to confirm these effects.

D4-androstenedione fell by 25-30% at both doses.

summary

B

grade

Leuprorelin acetate microspheres may suppress sex hormones and increase predicted adult height in girls with early and fast puberty, but the clinical relevance of these findings needs further investigation.

Median LH decreased from 2.7 (2.23-3.51) mIU/mL at T0 to 0.66 (0.48-1.22) mIU/mL at T4, P<0.001.

summary

C

grade

LHRH-targeted nanocarriers show promise in delivering bruceantin to pancreatic cancer cells, reducing tumor growth in preclinical models.

Tumor growth reduced by ~72.4% relative to controls.

summary

B

grade

This case report illustrates a rare instance of a male breast cancer patient surviving 8 years post-diagnosis, highlighting the need for awareness of pseudocirrhosis in this population.

Not reported in abstract.

summary

B

grade

Leuprorelin 22.5mg may minimize hospital time for prostate cancer patients compared to degarelix, which tends to cause more discomfort.

Not reported in abstract.

summary

B

grade

This case illustrates that atypical manifestations like macrocephaly and hyperostosis frontalis interna can occur in Rett syndrome, highlighting the need for comprehensive evaluations.

+2.5 SD macrocephaly at age 16

summary